Display options
Cite
Woodhead JL, Yang K, Brouwer KL, et al. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI. CPT Pharmacometrics Syst Pharmacol. 2014;3:e123doi: 10.1038/psp.2014.21.
Woodhead, J. L., Yang, K., Brouwer, K. L., Siler, S. Q., Stahl, S. H., Ambroso, J. L., Baker, D., Watkins, P. B., & Howell, B. A. (2014). Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI. CPT: pharmacometrics & systems pharmacology, 3e123. https://doi.org/10.1038/psp.2014.21
Woodhead, J L, et al. "Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI." CPT: pharmacometrics & systems pharmacology vol. 3 (2014): e123. doi: https://doi.org/10.1038/psp.2014.21
Woodhead JL, Yang K, Brouwer KL, Siler SQ, Stahl SH, Ambroso JL, Baker D, Watkins PB, Howell BA. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI. CPT Pharmacometrics Syst Pharmacol. 2014 Jul 09;3:e123. doi: 10.1038/psp.2014.21. PMID: 25006780; PMCID: PMC4120015.
Copy Download .nbib Format: NLM
Share it on

CPT Pharmacometrics Syst Pharmacol. 2014 Jul 09;3:e123. doi: 10.1038/psp.2014.21.

Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI.

CPT: pharmacometrics & systems pharmacology

J L Woodhead, K Yang, K L R Brouwer, S Q Siler, S H Stahl, J L Ambroso, D Baker, P B Watkins, B A Howell

Affiliations

  1. The Hamner-UNC Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA.
  2. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  3. DMPK, Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, UK.
  4. Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
  5. Investigative Preclinical Toxicology, Safety Assessment, GlaxoSmithKline R&D, Ware, UK.

PMID: 25006780 PMCID: PMC4120015 DOI: 10.1038/psp.2014.21

Abstract

Bile salt export pump (BSEP) inhibition has been proposed to be an important mechanism for drug-induced liver injury (DILI). Modeling can prioritize knowledge gaps concerning bile acid (BA) homeostasis and thus help guide experimentation. A submodel of BA homeostasis in rats and humans was constructed within DILIsym, a mechanistic model of DILI. In vivo experiments in rats with glibenclamide were conducted, and data from these experiments were used to validate the model. The behavior of DILIsym was analyzed in the presence of a simulated theoretical BSEP inhibitor. BSEP inhibition in humans is predicted to increase liver concentrations of conjugated chenodeoxycholic acid (CDCA) and sulfate-conjugated lithocholic acid (LCA) while the concentration of other liver BAs remains constant or decreases. On the basis of a sensitivity analysis, the most important unknowns are the level of BSEP expression, the amount of intestinal synthesis of LCA, and the magnitude of farnesoid-X nuclear receptor (FXR)-mediated regulation.

References

  1. Drug Metab Dispos. 2012 Jan;40(1):139-50 - PubMed
  2. Toxicol Lett. 2002 Feb 7;126(3):197-203 - PubMed
  3. Semin Liver Dis. 2000;20(3):273-92 - PubMed
  4. Hepatology. 2006 Jul;44(1):62-74 - PubMed
  5. Liver Int. 2007 Feb;27(1):137-44 - PubMed
  6. Med Hypotheses. 1986 Jan;19(1):57-69 - PubMed
  7. Toxicology. 2001 Oct 5;167(1):83-98 - PubMed
  8. Toxicol Lett. 2005 Jan 15;155(1):41-50 - PubMed
  9. J Lipid Res. 2012 Oct;53(10):2231-2241 - PubMed
  10. Nucl Recept Signal. 2010 Nov 19;8:e005 - PubMed
  11. Drug Metab Rev. 2004 Oct;36(3-4):703-22 - PubMed
  12. Toxicol Lett. 1992 Jul;61(2-3):291-304 - PubMed
  13. Neth J Med. 1992 Jun;40(5-6):305-7 - PubMed
  14. Hepatology. 1991 Nov;14(5):920-6 - PubMed
  15. Scand J Gastroenterol. 1977;12(4):395-400 - PubMed
  16. World J Gastroenterol. 2011 May 14;17(18):2349-52 - PubMed
  17. J Pharmacol Exp Ther. 2012 Aug;342(2):529-40 - PubMed
  18. Drug Metab Dispos. 2014 Mar;42(3):318-22 - PubMed
  19. Biochem Biophys Res Commun. 2005 May 6;330(2):395-9 - PubMed
  20. Chem Res Toxicol. 2012 Aug 20;25(8):1616-32 - PubMed
  21. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8 - PubMed
  22. Gut. 2003 Aug;52(8):1170-7 - PubMed
  23. Ann Intern Med. 1987 Jun;106(6):837-9 - PubMed
  24. Gastroenterology. 1997 Jan;112(1):226-35 - PubMed
  25. Front Biosci (Landmark Ed). 2009 Jan 01;14:2584-98 - PubMed
  26. Toxicol Sci. 2007 May;97(1):1-3 - PubMed
  27. Drug Metab Rev. 2013 Feb;45(1):145-55 - PubMed
  28. Drug Metab Dispos. 2012 Jan;40(1):130-8 - PubMed
  29. J Steroid Biochem Mol Biol. 2012 Jul;130(3-5):147-58 - PubMed
  30. Clin Pharmacol Ther. 2011 Aug;90(2):279-86 - PubMed
  31. J Lipid Res. 1989 May;30(5):719-30 - PubMed
  32. AAPS PharmSciTech. 2009;10(2):482-7 - PubMed
  33. J Biol Chem. 1994 Jul 29;269(30):19375-9 - PubMed
  34. J Lipid Res. 2009 Oct;50(10):1955-66 - PubMed
  35. J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):527-41 - PubMed
  36. Drug Metab Dispos. 2011 Dec;39(12):2395-402 - PubMed
  37. Lancet. 1975 Sep 27;2(7935):579-81 - PubMed

Publication Types

Grant support